Bank of Montreal’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$183K Sell
10,185
-15,630
-61% -$296K ﹤0.01% 3042
2026
Q1
$562K Buy
25,815
+10,685
+71% +$207K ﹤0.01% 2339
2025
Q4
$326K Buy
15,130
+2,279
+18% +$48K ﹤0.01% 2541
2025
Q3
$248K Sell
12,851
-26,745
-68% -$477K ﹤0.01% 2646
2025
Q2
$677K Sell
39,596
-110,514
-74% -$4.71M ﹤0.01% 2106
2025
Q1
$9.58M Sell
150,110
-6,308
-4% -$664K ﹤0.01% 944
2024
Q4
$19M Sell
156,418
-29,174
-16% -$3.58M 0.01% 766
2024
Q3
$23.1M Buy
185,592
+7,702
+4% +$1.06M 0.01% 726
2024
Q2
$29.6M Buy
177,890
+1,050
+0.6% +$135K 0.01% 634
2024
Q1
$23.1M Buy
176,840
+24,290
+16% +$2.98M 0.01% 689
2023
Q4
$14.9M Sell
152,550
-119,663
-44% -$11.5M ﹤0.01% 885
2023
Q3
$32.5M Buy
272,213
+174,299
+178% +$19.7M 0.01% 557
2023
Q2
$12.9M Buy
97,914
+62,921
+180% +$8.11M ﹤0.01% 915
2023
Q1
$4.83M Sell
34,993
-20,356
-37% -$2.64M ﹤0.01% 1250
2022
Q4
$7.31M Sell
55,349
-4,755
-8% -$551K ﹤0.01% 1114
2022
Q3
$6.76K Sell
60,104
-47,492
-44% -$4.79M ﹤0.01% 1193
2022
Q2
$8.15K Sell
107,596
-373,770
-78% -$27.5M ﹤0.01% 1157
2022
Q1
$37.8M Buy
481,366
+460,768
+2,237% +$35.3M 0.02% 568
2021
Q4
$1.87M Sell
20,598
-261,711
-93% -$22.4M ﹤0.01% 1612
2021
Q3
$25.6M Buy
282,309
+277,393
+5,643% +$21.4M 0.01% 807
2021
Q2
$395K Buy
4,916
+1,041
+27% +$78.9K ﹤0.01% 2951
2021
Q1
$278K Sell
3,875
-94,610
-96% -$8.73M ﹤0.01% 2964
2020
Q4
$8.84M Sell
98,485
-15,950
-14% -$2.36M 0.01% 1082
2020
Q3
$16M Buy
114,435
+25,000
+28% +$3.8M 0.01% 669
2020
Q2
$15.2M Buy
89,435
+85,405
+2,119% +$11.6M 0.01% 676
2020
Q1
$387K Sell
4,030
-24,469
-86% -$2.8M ﹤0.01% 2092
2019
Q4
$3.68M Sell
28,499
-76
-0.3% -$7.67K ﹤0.01% 1533
2019
Q3
$2.15M Sell
28,575
-29,239
-51% -$3.45M ﹤0.01% 1639
2019
Q2
$8.79M Sell
57,814
-10,767
-16% -$1.31M 0.01% 949
2019
Q1
$8.17M Sell
68,581
-82,554
-55% -$10.6M 0.01% 934
2018
Q4
$16.5M Buy
151,135
+51,859
+52% +$6.49M 0.02% 617
2018
Q3
$16M Sell
99,276
-8,657
-8% -$1.18M 0.01% 738
2018
Q2
$14.3M Buy
107,933
+42,982
+66% +$4.05M 0.01% 733
2018
Q1
$4.81M Sell
64,951
-20,756
-24% -$1.38M ﹤0.01% 1160
2017
Q4
$4.77M Buy
85,707
+1,103
+1% +$58.4K ﹤0.01% 1146
2017
Q3
$3.84M Sell
84,604
-14,171
-14% -$566K ﹤0.01% 1281
2017
Q2
$3.33M Hold
98,775
﹤0.01% 1362
2017
Q1
$2.92M Buy
98,775
+996
+1% +$30.8K ﹤0.01% 1323
2016
Q4
$3.35M Sell
97,779
-62,581
-39% -$2.51M ﹤0.01% 1257
2016
Q3
$9.85M Sell
160,360
-100,941
-39% -$3.05M 0.01% 816
2016
Q2
$4.98M Buy
261,301
+239,179
+1,081% +$4.43M 0.01% 1103
2016
Q1
$432K Buy
22,122
+21,466
+3,272% +$375K ﹤0.01% 2106
2015
Q4
$24K Buy
656
+141
+27% +$4.57K ﹤0.01% 3332
2015
Q3
$16K Hold
515
﹤0.01% 3330
2015
Q2
$16K Buy
515
+100
+24% +$2.04K ﹤0.01% 3371
2015
Q1
$5K Hold
415
﹤0.01% 3637
2014
Q4
$6K Buy
415
+249
+150% +$4.22K ﹤0.01% 3668
2014
Q3
$4K Sell
166
-940
-85% -$21.2K ﹤0.01% 3836
2014
Q2
$33K Buy
1,106
+940
+566% +$29.7K ﹤0.01% 3379
2014
Q1
$4K Sell
166
-100
-38% -$2.55K ﹤0.01% 3833
2013
Q4
$5K Hold
266
﹤0.01% 3542
2013
Q3
$13K Buy
266
+100
+60% +$3.85K ﹤0.01% 3353
2013
Q2
$6K Buy
+166
New +$5.94K ﹤0.01% 3411

Other funds holding SRPT

Bank of Montreal's SRPT Position: Q2 2026 in Review

Bank of Montreal reduced its Sarepta Therapeutics (SRPT) stake by 61% in Q2 2026, selling an estimated $296K and leaving 10,185 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #3042.

Bank of Montreal first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $37.8M in Q1 2022. 298 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Bank of Montreal held 10,185 shares of Sarepta Therapeutics worth $183K as of Q2 2026.
  • Bank of Montreal sold 15,630 Sarepta Therapeutics shares in Q2 2026, an estimated $296K.
  • Sarepta Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #3042 holding.
  • Bank of Montreal first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Bank of Montreal's Sarepta Therapeutics position peaked at $37.8M in Q1 2022.
  • 298 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.